With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

5 Things to Know is CNBC's Morning Squawk newsletter, a before-the-bell briefing on the most important news, trends and analysis that investors need to start their trading day. Subscribe here to ...